Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 1
Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris
Authors Vakirlis E, Kastanis A, Ioannides D
Published 8 February 2008 Volume 2008:4(1) Pages 141—148
Efstratios Vakirlis, Athanasios Kastanis, Demetrios Ioannides
A’ Department of Dermatology, Aristotle University of Thessaloniki, Greece
Abstract: Psoriasis is one of the most common skin diseases. The mainstay of treatment for the vast majority of patients is topical therapy. A rising first-line treatment modality for psoriasis vulgaris is the two-compound ointment containing calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g (Dovobet®, Daivobet®, Taclonex®), which combines a vitamin D analog and a corticosteroid. This innovative formulation preserves the activity and bioavailability of the two components and many clinical studies have demonstrated that it has a greater efficacy, tolerability, and a rapid onset of action compared with its individual ingredients or tacalcitol.
Keywords: psoriasis, calcipotriol/betamethasone dipropionate, dovobet, daivobet, taclonex
© 2008 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.